
Ryvu Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
The total operating revenues amounted to $11.9M and increased by 42% compared to Q3 2022. Updated data from Phase Ib study of RVU120 in AML/HR-MDS to be presented at the upcoming American Society of Hematology (ASH) Annual Meeting in December. …